Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALXN2220 versus placebo in adults with ATTR-CM
CTR20241546Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cliramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), transthyretin amyloidosis (ATTR), sponsored by AstraZeneca. Started Jul 2024; status: active.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on CTR20241546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241546.